1020718-20-0

Basic information

• Product Name: 2-BROMO-6-FLUOROBENZOYL CHLORIDE
• Synonyms: 2-BROMO-6-FLUOROBENZOYL CHLORIDE
• CAS NO: 1020718-20-0
• Molecular Formula: C₇H₃BrClFO
• Molecular Weight: 237.4535232
• Product Categories: Fluorine series
• Mol File: 1020718-20-0.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 236℃
• Flash Point: 97℃
• Appearance: /
• Density: 1.742
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-BROMO-6-FLUOROBENZOYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-6-FLUOROBENZOYL CHLORIDE(1020718-20-0)
• EPA Substance Registry System: 2-BROMO-6-FLUOROBENZOYL CHLORIDE(1020718-20-0)

Safety Data

• Hazardous Substances Data: 1020718-20-0(Hazardous Substances Data)

Usage

General Description

2-Bromo-6-Fluorobenzoyl Chloride is an aromatic organic compound, represented by the molecular formula of C7H3BrClFO. 2-BROMO-6-FLUOROBENZOYL CHLORIDE consists of a benzene ring, which is one of the most common structures in organic chemistry, substituted by bromo, fluoro and benzoyl chloride groups. It is used in research and development laboratories, usually in the production of other complex organic compounds. It must be handled with care due to its highly corrosive nature and potential to cause severe burns and eye damage. Storage of 2-Bromo-6-Fluorobenzoyl Chloride should be in a cool, dry place away from any heat sources or open flames. Its application is mostly in the field of synthetic organic chemistry.

Upstream product

• 2252-37-1 2-bromo-6-fluorobenzoic acid 

Downstream Products

• 1447018-07-6 2-(benzylthio)-6-(2-bromo-6-(2-bromo-6-fluorobenzamido)benzamido)-N-methylbenzamide 
• 1888305-96-1 4-(2-bromo-6-fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide 

Relevant articles and documents

Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid

The aldo-keto reductase 1C3 (AKR1C3) isoform plays a vital role in the biosynthesis of androgens and is considered an attractive target in prostate cancer (PCa). No AKR1C3-targeted agent has to date been approved for clinical use. Flufenamic acid and indomethacine are non-steroidal anti-inflammatory drugs known to inhibit AKR1C3 in a non-selective manner as COX off-target effects are also observed. Recently, we employed a scaffold hopping approach to design a new class of potent and selective AKR1C3 inhibitors based on a N-substituted hydroxylated triazole pharmacophore. Following a similar strategy, we designed a new series focused around an acidic hydroxybenzoisoxazole moiety, which was rationalised to mimic the benzoic acid role in the flufenamic scaffold. Through iterative rounds of drug design, synthesis and biological evaluation, several compounds were discovered to target AKR1C3 in a selective manner. The most promising compound of series (6) was found to be highly selective (up to 450-fold) for AKR1C3 over the 1C2 isoform with minimal COX1 and COX2 off-target effects. Other inhibitors were obtained modulating the best example of hydroxylated triazoles we previously presented. In cell-based assays, the most promising compounds of both series reduced the cell proliferation, prostate specific antigen (PSA) and testosterone production in AKR1C3-expressing 22RV1 prostate cancer cells and showed synergistic effect when assayed in combination with abiraterone and enzalutamide. Structure determination of AKR1C3 co-crystallized with one representative compound from each of the two series clearly identified both compounds in the androstenedione binding site, hence supporting the biochemical data.

Ni-Catalyzed Reductive Arylcyanation of Alkenes

We disclose a Ni-catalyzed reductive arylcyanation of alkene using environmentally benign and nontoxic organo cyanating reagent N-cyano-N-phenyl-p-toluenesulfonamide. This reaction provides a new method for the rapid synthesis of cyano-substituted oxindoles and isoquinoline-1,3-diones and features high functional group tolerance. In addition, an enantioselective version was developed for the construction of enantiomerically enriched 3-cyanomethyl oxindole. This method has also been applied to the synthesis of natural alkaloids (+)-esermethole and (+)-physostigmine.

Design, synthesis and biological evaluation of novel 1-phenyl phenanthridin-6(5H)-one derivatives as anti-tumor agents targeting TOPK

T–lymphokine-activated killer cell–originated protein kinase (TOPK) is a serine-threonine mitogen-activated protein kinase that is highly expressed in many types of human cancer. Due to its important role in cancer progression, TOPK is becoming an attractive target in chemotherapeutic drug design. In this study, a series of 1-phenyl phenanthridin-6(5H)-one derivatives have been identified as a novel chemical class of TOPK inhibitors. Some of them displayed very potent anti-cancer activity with IC50s less than 100 nM, superior than reference compound OTS964. The most potent compound, 9g suppressed the growth of cancer cells by apoptosis and specifically inhibited the activities of TOPK. Oral administration of 9g effectively suppressed tumor growth with TGI >79.7% in colorectal cancer xenograft models, demonstrating superior efficacy compared to OTS964. Pharmacokinetic studies reveal its good oral bioavailability. Our findings therefore show that 9g is a specific inhibitor of TOPK both in vitro and in vivo that may be further developed as a potential therapeutic agent against colorectal cancer.